ReviewThe archives of bone and joint surgery2025
Osteosarcoma Management in the Precision Medicine Era: Bibliometric Analysis and Clinical Progress (2015-2024).
Review in The archives of bone and joint surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Quality Of Life and Functional Outcomes in Patients with Spinal Metastatic Bone Disease: A Retrospective Observational Study.The archives of bone and joint surgery · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Osteosarcoma, the most common high-grade malignant bone tumor, has experienced only limited progress in therapeutic options, highlighting the urgent need for more effective treatments. This review examines bibliometric trends and clinical developments in osteosarcoma research from 2015 to 2024, with a particular focus on precision medicine and personalized therapy. Methods: A search in the Web of Science Core Collection identified 17,476 osteosarcoma-related publications for bibliometric analysis. Key metrics, including publication trends, international collaborations, and emerging research topics, were evaluated using the Bibliometrix R package. Additionally, a clinical review examined recent innovations in diagnostic imaging, prognostic biomarkers, chemotherapy resistance, targeted therapies, immunotherapies, and surgical techniques. Results: Research publications on osteosarcoma steadily increased, peaking at 2,009 in 2021, with significant contributions from China, the United States, Japan, India, and Italy. Key research themes encompassed apoptosis, metastasis, chemotherapy resistance, and immunotherapy. Advances in imaging techniques, such as dynamic MRI and PET/CT, have significantly enhanced tumor staging and prediction of treatment response. Emerging biomarkers, including genetic alterations (TP53, RB1, MYC) and inflammatory markers, have become important prognostic tools. Surgical innovations, including patient-specific instrumentation and limb-sparing techniques, have improved patient outcomes. Furthermore, targeted therapies (kinase inhibitors, antibody-drug conjugates) and immunotherapies (CAR T-cell therapy, immune checkpoint inhibitors) have demonstrated promising results in clinical trials. Conclusion: Integrating bibliometric insights with clinical advancements underscores the importance of personalized approaches in osteosarcoma management. Predictive imaging biomarkers and precision-targeted therapies play a crucial role, and future research should focus on their clinical validation to enhance patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.